Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Jul 5, 2023
Date Accepted: Sep 9, 2024

The final, peer-reviewed published version of this preprint can be found here:

Exploring Public Sentiment on the Repurposing of Ivermectin for COVID-19 Treatment: Cross-Sectional Study Using Twitter Data

Kautsar AP, Sinuraya RK, van der Schans J, Postma MJ, Suwantika AA

Exploring Public Sentiment on the Repurposing of Ivermectin for COVID-19 Treatment: Cross-Sectional Study Using Twitter Data

JMIR Form Res 2025;9:e50536

DOI: 10.2196/50536

PMID: 40146987

PMCID: 11986376

Exploring Public Sentiment on the Repurposing of Ivermectin for COVID-19 Treatment: Cross-Sectional Study Using Twitter Data

  • Angga Prawira Kautsar; 
  • Rano Kurnia Sinuraya; 
  • Jurjen van der Schans; 
  • Maarten Jacobus Postma; 
  • Auliya A Suwantika

A sentiment analysis of 5051 Twitter posts from January 2022 found that 53.4% of them expressed positive views on ivermectin as a COVID-19 treatment, 35.6% of them were neutral, and 11% of them were negative, highlighting the polarized public perception and the need for careful interpretation of social media data in health communication.


 Citation

Please cite as:

Kautsar AP, Sinuraya RK, van der Schans J, Postma MJ, Suwantika AA

Exploring Public Sentiment on the Repurposing of Ivermectin for COVID-19 Treatment: Cross-Sectional Study Using Twitter Data

JMIR Form Res 2025;9:e50536

DOI: 10.2196/50536

PMID: 40146987

PMCID: 11986376

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.